$AVR

L1 Capital Pty Ltd sold $4.3M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 524,404 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.10 ($8.10–$8.15, $4.25M total) across 2 trades over 2026-07-31 to 2026-08-03.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Aug 4, 2026, 10:23 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The newest information is the disclosed sale size, price range, and post-transaction share count, which can influence short-term sentiment but lacks fundamental drivers in the text.

02

Market read

A $4.25M open-market sale by a 10% owner is newly disclosed, offering a modest sentiment signal for AVR without new business or financial guidance.

03

What to watch

Indirect holdings and the absence of a stated 10b5-1 plan do not, by themselves, confirm bearish expectations; traders should watch for subsequent Form 4s and any concurrent company disclosures.

Relevance 6/10Novelty 5/10Timing: filed today, covering sales from 2026-07-31 to 2026-08-03

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR), reported by L1 Capital Pty Ltd as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

Anteris Technologies Global Corp. (AVR) disclosed an open-market sale by a 10% owner, L1 Capital, totaling about $4.25M at ~$8.10/share.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or additional filings emerge.

Evidence & confidence

Form 4 shows an indirect open-market sale with no 10b5-1 plan stated, but the article provides no new operational, financial, or regulatory catalyst for AVR.

Market effects

Minimal, as this is a single-company insider transaction with no sector-wide regulatory or competitive change.

None indicated.

None indicated.

Counterpoint

The sale could be liquidity-driven or portfolio rebalancing, especially since the filing does not cite any adverse company development.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure, ticker AVR.

  • L1 Capital Pty Ltd

    Reporter of the indirect open-market sale totaling $4.25M across two trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.